Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings
November 28, 2023 07:00 ET
|
Praxis Precision Medicines, Inc.
BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare Conference
November 21, 2023 16:00 ET
|
Praxis Precision Medicines, Inc.
Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare Conference
Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies
November 16, 2023 08:00 ET
|
Praxis Precision Medicines, Inc.
Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsi
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results
November 07, 2023 07:00 ET
|
Praxis Precision Medicines, Inc.
Essential3 study initiated, with over 600 patients engaged in pre-recruitment observational study Elsunersen EMBRAVE study final dose completed, Praxis seeking FDA advice on advancing...
Praxis Precision Medicines to Present at Truist Securities BioPharma Symposium
November 02, 2023 08:00 ET
|
Praxis Precision Medicines, Inc.
Praxis Precision Medicines to Present at Truist Securities BioPharma Symposium
Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day
October 02, 2023 13:17 ET
|
Praxis Precision Medicines, Inc.
Positive results from preliminary analysis of PRAX-222 Part 1 showed 44% median reduction in seizures after three doses for SCN2A-gain-of-function pediatric patients Phase 3 (Essential3) program for...
Praxis Precision Medicines To Host Hybrid R&D Day on Monday, October 2, 2023
September 27, 2023 16:15 ET
|
Praxis Precision Medicines, Inc.
BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines to Present at H.C. Wainwright 25th Annual Global Investment Conference
September 07, 2023 08:00 ET
|
Praxis Precision Medicines, Inc.
BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines to Present Data from Epilepsy Portfolio at the 35th International Epilepsy Congress
August 31, 2023 08:00 ET
|
Praxis Precision Medicines, Inc.
BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International Congress
August 28, 2023 07:00 ET
|
Praxis Precision Medicines, Inc.
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...